Stock Events

Stock Events

Mainz Biomed N.V. 

$0.45
110
+$0+0% Today

Statistics

Day High
0.46
Day Low
0.43
52W High
-
52W Low
-
Volume
2,117
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

14AprExpected
Q2 2025
Next
-2.65
-2.1
-1.56
-1.01
Expected EPS
-1.01
Actual EPS
N/A

Financials

-2,424.52%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
1.79MRevenue
-43.3MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MYNZ.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Exact Sciences
EXAS
Mkt Cap20.03B
Exact Sciences Corp. offers Cologuard, a non-invasive stool DNA screening test for colorectal cancer, directly competing with Mainz Biomed's colorectal cancer detection technologies.
Guardant Health
GH
Mkt Cap12.31B
Guardant Health, Inc. provides liquid biopsy tests that detect cancer and cancer treatment targets, competing in the broader cancer diagnostics market.
Fulgent Genetics
FLGT
Mkt Cap525.3M
Fulgent Genetics, Inc. provides comprehensive genetic testing solutions for various diseases, including cancer, competing in the genetic testing market.
Qiagen NV
QGEN
Mkt Cap8.46B
Qiagen N.V. offers sample and assay technologies for molecular diagnostics, including cancer, competing in the molecular diagnostics market.
Pacific Biosciences of California
PACB
Mkt Cap404.68M
Pacific Biosciences of California, Inc. offers sequencing systems that could be used in cancer research and diagnostics, indirectly competing in the genomics space.
Illumina
ILMN
Mkt Cap19.48B
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis, which are crucial in cancer research and diagnostics, making it a competitor in the genomics field.
TG Therapeutics
TGTX
Mkt Cap5.35B
TG Therapeutics, Inc. focuses on developing treatments for B-cell malignancies and autoimmune diseases, competing in the broader oncology and biopharmaceutical market.
Adaptive Biotechnologies
ADPT
Mkt Cap2.28B
Adaptive Biotechnologies Corp. offers clonoSEQ, a diagnostic test for detecting minimal residual disease in blood cancers, competing in the cancer diagnostics and monitoring market.

About

Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes its IVD kits to third-party laboratories. The company has a collaboration agreement with Thermo Fisher Scientific Inc. for the development and commercialization of colorectal cancer screening product. Mainz Biomed N.V. was founded in 2008 and is based in Mainz, Germany.
Show more...
CEO
ISIN
NL0015000LC2

Listings

XNAS
US
MYNZ
F
DE
4TO.F
BOATS
BOATS
MYNZ.BOATS
XNAS
US
QUCY

0 Comments

Share your thoughts

FAQ

What is Mainz Biomed N.V. stock price today?▼
The current price of MYNZ.BOATS is $0.45 USD — it has increased by +0% in the past 24 hours. Watch Mainz Biomed N.V. stock price performance more closely on the chart.
What is Mainz Biomed N.V. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Mainz Biomed N.V. stocks are traded under the ticker MYNZ.BOATS.
When is the next Mainz Biomed N.V. earnings date?▼
Mainz Biomed N.V. is going to release the next earnings report on April 14, 2026.
What were Mainz Biomed N.V. earnings last quarter?▼
MYNZ.BOATS earnings for the last quarter are -2.65 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Mainz Biomed N.V. revenue for the last year?▼
Mainz Biomed N.V. revenue for the last year amounts to 1.79M USD.
What is Mainz Biomed N.V. net income for the last year?▼
MYNZ.BOATS net income for the last year is -43.3M USD.
When did Mainz Biomed N.V. complete a stock split?▼
Mainz Biomed N.V. has not had any recent stock splits.